- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Kevin Kalinsky, MD, MS | Authors
Articles
Kevin Kalinsky, MD, MS, on the Aim of the Phase 3 RxPONDER Trial in Breast Cancer Subtype
January 13, 2021
A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.
Kevin Kalinsky, MD, MS, on Implications of the Phase 3 RxPONDER Trial in Breast Cancer
December 18, 2020
The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.